• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4186.TWO
Share

Taiwan Advance Bio-Pharmaceutical Inc. Stocks

NT$ 6.96Last Updated 16.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 21.30M

NT$ 6.96
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Taiwan Advance Bio-Pharmaceutical Inc. is a biotechnology enterprise with a substantial international presence, conducting operations across numerous countries such as China, Germany, the USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, and Pakistan, in addition to other global markets. Founded in 1989 and headquartered in New Taipei City, Taiwan, the company delivers a comprehensive array of products and services. Its offerings encompass diagnostic kits for ensuring food safety, alongside tailored customization services for ELISA, rapid, and chemical test kits, and expert consultation for setting up food safety laboratories. The firm also specializes in manufacturing both monoclonal and polyclonal antibody products. Furthermore, its portfolio includes rapid screening tests for illicit substances. It provides essential cell banking services for the secure preservation of both newborn and adult stem cells. The company also operates a dedicated drug testing facility, performing analyses on urine and hair samples to detect and identify drug abuse.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 09:39

The euro fell amid protests in France and geopolitical tensions

18.10.2026 21:01

IPO roundup: Anthropic valuation falls, SpaceX lifts space-sector investment

17.10.2026 21:12

DeepSeek unveils updated AI model claimed to be faster than its predecessor

17.10.2026 16:01

Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026